OCULAR THERAPEUTIX, INC (OCUL) Form 8-K — Nov 9, 2026

$OCULForm 8-KItems 5.02Filed Nov 9, 2026, 7:28 AM ET0001104659-26-124159Original filing

Ocular Therapeutix elected Riad Sherif, M.D., to its Board of Directors effective November 6, 2026, as a Class I director standing for re-election at the 2027 annual meeting. Dr. Sherif is CEO of Oculis Holding AG and a former senior executive at Alcon and Novartis, bringing deep ophthalmology industry experience to the board. In connection with his election, Dr.

Key figures

Rsu award shares: 28000
Option exercise price: 6.6
Director option shares: 88000

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.